Göcze P M, Szabò D G, Than G N, Krommer K F, Csaba I F, Bohn H
Department of Obstetrics and Gynecology, University Medical School, Pécs, Hungary.
Gynecol Obstet Invest. 1991;32(2):107-11. doi: 10.1159/000293006.
Placental protein 4 (PP-4), a recently characterized glycoprotein from human placenta, was studied using a specific double-antibody radioimmunoassay in sera of 130 volunteers, 76 ovarian tumor patients and in ovarian tumor cyst fluid and ascites of 21 patients. Elevated levels (greater than 3 micrograms/l) were found in 45 of 52 ovarian cancer patients (86.5%). PP-4 levels correlated significantly with staging. 31 patients with malignant ovarian tumor were monitored on 2-9 occasions during 5-82 weeks. Rising or falling levels of PP-4 correlated with progression or regression of disease in 25 of 31 instances (80.6%). Elevated levels were found in 10 of 24 benign and borderline ovarian tumors. Elevated PP-4 level does not indicate malignancy in each case. PP-4 can be regarded as tumor-associated antigen and an tumor marker in oncological practice.
胎盘蛋白4（PP - 4）是一种最近从人胎盘中鉴定出的糖蛋白，我们使用特异性双抗体放射免疫分析法对130名志愿者、76名卵巢肿瘤患者的血清以及21名患者的卵巢肿瘤囊液和腹水中的该蛋白进行了研究。在52名卵巢癌患者中有45名（86.5%）检测到PP - 4水平升高（大于3微克/升）。PP - 4水平与分期显著相关。31例恶性卵巢肿瘤患者在5至82周内接受了2至9次监测。在31例中有25例（80.6%）PP - 4水平的升高或降低与疾病的进展或消退相关。在24例良性和交界性卵巢肿瘤中有10例检测到PP - 4水平升高。PP - 4水平升高并不表明在每种情况下均为恶性。在肿瘤学实践中，PP - 4可被视为肿瘤相关抗原和一种肿瘤标志物。
